# Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.

> **NCT04178057** · PHASE1 · UNKNOWN · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Brain Tumor

## Interventions

- **BIOLOGICAL:** GB222 3mg/kg
- **BIOLOGICAL:** GB222 5mg/kg
- **BIOLOGICAL:** GB222 7.5mg/kg
- **BIOLOGICAL:** GB222 10mg/kg

## Key facts

- **NCT ID:** NCT04178057
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-16
- **Primary completion:** 2020-12
- **Final completion:** 2021-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04178057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04178057, "Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04178057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*